Member Info for Candid

Indeed, it sounds like Star Zinc is just waiting for the zinc circuit completion at Sable and then is ready to start supplying high grade ore of 20-25%. Said Zambia is working normally during this period.
CB also looked excited to point out the potential at Kash*tu where he said 50m tonnes at 2-3% zinc, steady state with a very good chance of upgrading this higher. At current zinc prices and taking 3% zinc that comes to around $3Billion of in-ground zinc metal!

I’m hearing that many railway companies around the globe are not operating and are using the current downtime to improve tracks and infrastructure. This is an ideal time for MNO’s Corridor AI system to demonstrate it’s value. I would not be surprised to hear an update about increasing progress on projects and maybe even some new contract wins.

Looking better here, perhaps the low is in and a rerate is due over the next 6 months, production expected early next year. Once the environmental permit is in this should move up fast. The shenanigans at one of our peers Kalium has possibly rubbed off on sentiment here but it is not at all an issue for us

In 2016 Galileo was selling it’s stake in Glenover for $4m to it’s partner Ferminore Pty Ltd, but this was cancelled by mutual agreement as they said ‘developments in the Phosphate market led to considerable scope for value enhancement’
So a few years down the line they now have:
1) a larger stake
2) involved a Major Phosphate Producer in testing, due diligence and offtake talks
3) submitted a mining right application to the DMR (due anytime now)
4) rare earths have emerged as critical minerals and REE projects have increased in value

So surely GLR’s stake in Glenover should now be worth more then the previous $4m sale price.
Thoughts?

Will likely see an RNS tomorrow, should see an increase in mined bitcoins reflecting the growing hardware and the lower average difficulty in April vs March

not sure if posted here already but here it is anyway.

Synairgen (SNG) : Corp

COVID-19 trial (SG016) update

Key data

Share price (p) 52.5
Target price (p) 120.0
Market cap (£m) 78.5
Enterprise value (£m) 76.0
Synairgen announced that more than 75 out of the targeted 100 hospitalised COVID-19 patients have been dosed with SNG001. Additionally, an amendment to Synairgen’s Phase II study (SG016) of SNG001 (inhaled interferon – IFNß-1a) was granted and listed on the NHS Research Authority website on 29 April. The amendment will allow the study to start enrolling patients with SARS-CoV-2 in the home setting, within 72 hours of symptoms first developing. The aim is to be able to treat COVID-19 patients earlier in their infection given that hospitalised patients, included in the 100-patient part of SG016, will typically have had COVID-19 symptoms for an average of 10-11 days prior to admission. This forms part of the broader clinical activities planned for SNG001 and described at the time of the recent placing. We still expect first data readout from hospitalised patients by June 2020. We reiterate our 120p target price with the prospect that this could rise by up to 240p on a positive outcome of first data readout.

Mark Brewer

The amendment sounds like a very positive development as there is a potential for this treatment to stop the virus worsening when treated early and as a result prevent hospitalisation.
If this proves successful this will be a major breakthrough and will likely be prescribed to everybody showing symptoms! The volume of this is massive compared to the volume of people who get hospitalised.
What’s more it’s not only for Covid-19 but any respiratory viral infection that may develop in the future.

“We believe that it is important to assess SNG001 early in the infection cycle.
This substantial amendment is being submitted to allow patients to be dosed in the home environment within 72 hours of symptoms first developing with either SNG001 or placebo daily for 14 days. The Pilot phase of SG016 now includes 100 patients initiated in hospital and 120 patients initiated in the home setting”

Have a look at the 3 year chart, 100p looks like a first target and then 150p

All diagnostic companies are down this morning, AVCT, ODX, NCYT with exception of OBD who have have an RNS this morning, probably just a normal pullback before next leg resumes

About time this starts moving, still way undervalued compared to peers, for example Hive is now on a market cap of £80m compared to our £20m market cap

Fruta del Norte is a gold mine in Equador

Newcrest Mining has launched a $1 billion capital raising through an institutional placement.

Source, Financial Review

We know that Landsdowne Partners have been reducing their holding here and this is probably keeping the price down, however I would not be too concerned as they are simply de-risking their rather large holding whenever there is the opportunity to do so (i.e in this period of high liquidity)
In fact this creates a buying opportunity for others in the lead-up to trial results

Maybe a question for any longterm holders here..
Any thoughts on when/if the loan notes will be converted to shares?
Currently GDR have the following two loan arrangements:

1) $8m from Global Health Investment fund
($2m - option to convert 28.75p a share)
($6m - option to convert at 150p a share)

2) £2.5m loan from BGF
(£2.5m - option to convert at 28.75p a share)

2020 outlook is outstanding: costs greatly reduced, latest hardware installed, business continuity unaffected. Looking forward to a material increase in revenue and profit

Why is no mention of Covid-19 when this same deal was announced recently on 15th April?

https://www.morningstar.co.uk/uk/news/AN_1586929966103260400/deepmatter-inks-digitalglassware-platform-deal-with-cancer-research-uk.aspx

What’s good about this is that there are only 35m shares in issue, which means steep rises are inevitable..

I would say a big 3 weeks ahead as we countdown into BTC halving mid-May.
This is likely the main catalyst driving the current rally and more people will jump in as this builds.
Traders will be liquidating short positions as their stop losses get taken out.

Wouldn’t it be good is promising companies like GDR could obtain funding to accelerate efforts for Covid. A pledging campaign starts in May.

https://www.who.int/docs/default-source/coronaviruse/access-to-covid-19-tools-(act)-accelerator-call-to-action-24april2020.pdf?sfvrsn=5f721eaf_4&download=true

Must be some short covering adding fuel to the BTC fire now